These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 19199919)
1. Metallothioneins and platinum(II) anti-tumor compounds. Knipp M Curr Med Chem; 2009; 16(5):522-37. PubMed ID: 19199919 [TBL] [Abstract][Full Text] [Related]
2. Reaction of Zn7metallothionein with cis- and trans-[Pt(N-donor)2Cl2] anticancer complexes: trans-Pt(II) complexes retain their N-donor ligands. Knipp M; Karotki AV; Chesnov S; Natile G; Sadler PJ; Brabec V; Vasák M J Med Chem; 2007 Aug; 50(17):4075-86. PubMed ID: 17665893 [TBL] [Abstract][Full Text] [Related]
3. Capturing platinum in cisplatin: kinetic reactions with recombinant human apo-metallothionein 1a. Wong DL; Stillman MJ Metallomics; 2018 May; 10(5):713-721. PubMed ID: 29687824 [TBL] [Abstract][Full Text] [Related]
4. Interaction of metallothionein-2 with platinum-modified 5'-guanosine monophosphate and DNA. Karotki AV; Vasák M Biochemistry; 2008 Oct; 47(41):10961-9. PubMed ID: 18803406 [TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells. Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495 [TBL] [Abstract][Full Text] [Related]
6. Reaction of human metallothionein-3 with cisplatin and transplatin. Karotki AV; Vasák M J Biol Inorg Chem; 2009 Sep; 14(7):1129-38. PubMed ID: 19536566 [TBL] [Abstract][Full Text] [Related]
7. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Knox RJ; Friedlos F; Lydall DA; Roberts JJ Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077 [TBL] [Abstract][Full Text] [Related]
8. The reaction of a platinated methionine motif of CTR1 with cysteine and histidine is dependent upon the type of precursor platinum complex. Ma G; Wu Q; Wu X; Arnesano F; Natile G; Sletten E; Liu Y J Inorg Biochem; 2015 Dec; 153():239-246. PubMed ID: 26235215 [TBL] [Abstract][Full Text] [Related]
9. Comparative cisplatin reactivity towards human Zn7-metallothionein-2 and MTF-1 zinc fingers: potential implications in anticancer drug resistance. Bulathge AW; Villones RLE; Herbert FC; Gassensmith JJ; Meloni G Metallomics; 2022 Sep; 14(9):. PubMed ID: 36026541 [TBL] [Abstract][Full Text] [Related]
10. Platinum binding to metallothionein. Analysis of circular dichroism spectra of complexes formed between metallothionein and platinum from cis- and trans-diamminedichloroplatinum. Zhang B; Tang W; Gao S; Zhou Y J Inorg Biochem; 1995 Apr; 58(1):9-19. PubMed ID: 7738541 [TBL] [Abstract][Full Text] [Related]
11. Cisplatin and platinum drugs at the molecular level. (Review). Boulikas T; Vougiouka M Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679 [TBL] [Abstract][Full Text] [Related]
12. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes. Siddik ZH; al-Baker S; Thai G; Khokhar AR Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929 [TBL] [Abstract][Full Text] [Related]
13. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts. Kasparkova J; Novakova O; Farrell N; Brabec V Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292 [TBL] [Abstract][Full Text] [Related]
14. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Dedon PC; Borch RF Biochem Pharmacol; 1987 Jun; 36(12):1955-64. PubMed ID: 2954556 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization, and biological evaluation of new tetrazole-based platinum(II) and palladium(II) chlorido complexes--potent cisplatin analogues and their trans isomers. Serebryanskaya TV; Yung T; Bogdanov AA; Shchebet A; Johnsen SA; Lyakhov AS; Ivashkevich LS; Ibrahimava ZA; Garbuzenco TS; Kolesnikova TS; Melnova NI; Gaponik PN; Ivashkevich OA J Inorg Biochem; 2013 Mar; 120():44-53. PubMed ID: 23305964 [TBL] [Abstract][Full Text] [Related]
16. Delivery of platinum (II) drugs with bulky ligands in trans-geometry for overcoming cisplatin drug resistance. Yang X; Yu Y; Huang X; Chen Q; Wu H; Wang R; Qi R; Miao Y; Qiu Y Mater Sci Eng C Mater Biol Appl; 2019 Mar; 96():96-104. PubMed ID: 30606608 [TBL] [Abstract][Full Text] [Related]
17. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines. Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637 [TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro binding of platinum to metallothionein. Zelazowski AJ; Garvey JS; Hoeschele JD Arch Biochem Biophys; 1984 Feb; 229(1):246-52. PubMed ID: 6538400 [TBL] [Abstract][Full Text] [Related]
19. The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review). Chaney S Int J Oncol; 1995 Jun; 6(6):1291-305. PubMed ID: 21556672 [TBL] [Abstract][Full Text] [Related]
20. Inversion of the cis geometry requirement for cytotoxicity in structurally novel platinum(II) complexes containing the bidentate N,O-donor pyridin-2-yl-acetate. Bierbach U; Sabat M; Farrell N Inorg Chem; 2000 May; 39(9):1882-90. PubMed ID: 11428108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]